U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C18H24N4O2
Molecular Weight 328.4088
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 7-HYDROXYGRANISETRON

SMILES

CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C4=C1C(O)=CC=C4

InChI

InChIKey=AJEBHUMZPBDLQF-CLLJXQQHSA-N
InChI=1S/C18H24N4O2/c1-21-12-5-3-6-13(21)10-11(9-12)19-18(24)16-14-7-4-8-15(23)17(14)22(2)20-16/h4,7-8,11-13,23H,3,5-6,9-10H2,1-2H3,(H,19,24)/t11-,12+,13-

HIDE SMILES / InChI

Molecular Formula C18H24N4O2
Molecular Weight 328.4088
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Wed Apr 02 06:48:28 GMT 2025
Edited
by admin
on Wed Apr 02 06:48:28 GMT 2025
Record UNII
GG8LX5R3UF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
7-HYDROXYGRANISETRON
Common Name English
1H-INDAZOLE-3-CARBOXAMIDE, 7-HYDROXY-1-METHYL-N-((3-ENDO)-9-METHYL-9-AZABICYCLO(3.3.1)NON-3-YL)-
Preferred Name English
1H-INDAZOLE-3-CARBOXAMIDE, 7-HYDROXY-1-METHYL-N-(9-METHYL-9-AZABICYCLO(3.3.1)NON-3-YL)-, ENDO-
Systematic Name English
7-HYDROXY-1-METHYL-N-((3-ENDO)-9-METHYL-9-AZABICYCLO(3.3.1)NON-3-YL)-1H-INDAZOLE-3-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
FDA UNII
GG8LX5R3UF
Created by admin on Wed Apr 02 06:48:28 GMT 2025 , Edited by admin on Wed Apr 02 06:48:28 GMT 2025
PRIMARY
CAS
133841-15-3
Created by admin on Wed Apr 02 06:48:28 GMT 2025 , Edited by admin on Wed Apr 02 06:48:28 GMT 2025
PRIMARY
CAS
2407763-22-6
Created by admin on Wed Apr 02 06:48:28 GMT 2025 , Edited by admin on Wed Apr 02 06:48:28 GMT 2025
ALTERNATIVE
Related Record Type Details
PARENT -> METABOLITE ACTIVE
After both oral and intravenous administration, the metabolite is present at about 10% of that of the parent (Clarke et al., 1994; Boppana, 1995). Assuming similar free fractions, it can be estimated that the metabolite would contribute about 20% of the activity of the parent.